Literature DB >> 22317953

Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands.

Johan L Dikken1, Valery E Lemmens, Michel W J M Wouters, Bas P Wijnhoven, Peter D Siersema, Grard A Nieuwenhuijzen, Johanna W van Sandick, Annemieke Cats, Marcel Verheij, Jan Willem Coebergh, Cornelis J H van de Velde.   

Abstract

INTRODUCTION: A worldwide increasing incidence is seen for oesophageal adenocarcinoma, but not for oesophageal squamous cell carcinoma (SCC) and gastric cardia adenocarcinoma. Purposes of the current study were to evaluate the changing incidence rates of oesophageal and gastric cardia cancer, and to assess survival trends. PATIENTS AND METHODS: Patients diagnosed with oesophageal adenocarcinoma (N=12,195) or SCC (N=9046), or gastric cardia adenocarcinoma (N=9900) between 1989 and 2008 in the Netherlands were included. Changes in European Standard Population (ESP) and relative survival over time were evaluated.
RESULTS: Incidence rates for oesophageal adenocarcinoma increased in males (+7.5%, P<0.001) and females (+5.2%, P<0.001), while the incidence for oesophageal SCC remained stable in males (-0.2%, P=0.6) and slightly increased in females (+1.7%, P=0.001). The incidence for gastric cardia cancer decreased in males (-1.2%, P<0.006), and remained stable in females (-0.2%, P=0.7). Five-year survival for both M0 and M1 oesophageal carcinoma doubled over the last 20 years. No significant changes in survival were found for M0 and M1 gastric cardia carcinoma. DISCUSSION: In the Netherlands, a rising incidence is seen for oesophageal adenocarcinoma, but not for gastric cardia adenocarcinoma. This finding most likely reflects true changes in disease burden, rather than being the result of changes in diagnosis or classification. The increased survival for oesophageal carcinoma can be attributed to centralisation of surgery, and an increased use of multimodality therapy, factors hardly acknowledged for gastric cancer.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22317953     DOI: 10.1016/j.ejca.2012.01.009

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  37 in total

1.  Tumor microRNA-126 controls cell viability and associates with poor survival in patients with esophageal adenocarcinoma.

Authors:  Ela Toxopeus; N Lynam-Lennon; K Biermann; G Dickens; P E de Ruiter; Jjb van Lanschot; J V Reynolds; Bpl Wijnhoven; J O'Sullivan; Ljw van der Laan
Journal:  Exp Biol Med (Maywood)       Date:  2019-08-07

Review 2.  Current understanding of the functional roles of aberrantly expressed microRNAs in esophageal cancer.

Authors:  Christine Kestens; Peter D Siersema; Jantine W P M van Baal
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Three-field lymph node dissection in esophageal cancer surgery.

Authors:  Satoru Matsuda; Hiroya Takeuchi; Hirofumi Kawakubo; Yuko Kitagawa
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

4.  Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma.

Authors:  Hiroharu Yamashita; Yasuyuki Seto; Takeshi Sano; Hiroyasu Makuuchi; Nobutoshi Ando; Mitsuru Sasako
Journal:  Gastric Cancer       Date:  2016-10-28       Impact factor: 7.370

5.  Recurrent laryngeal nerve injury after esophagectomy for esophageal cancer: incidence, management, and impact on short- and long-term outcomes.

Authors:  Martijn G Scholtemeijer; Maarten F J Seesing; Hylke J F Brenkman; Luuk M Janssen; Richard van Hillegersberg; Jelle P Ruurda
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

6.  Trends in gastric cancer incidence: a period and birth cohort analysis in a well-defined French population.

Authors:  Chapelle Nicolas; Manfredi Sylvain; Lepage Come; Faivre Jean; Bouvier Anne-Marie; Jooste Valérie
Journal:  Gastric Cancer       Date:  2015-06-29       Impact factor: 7.370

7.  Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands.

Authors:  S Kroep; I Lansdorp-Vogelaar; J H Rubenstein; V E P P Lemmens; E B van Heijningen; N Aragonés; M van Ballegooijen; J M Inadomi
Journal:  Am J Gastroenterol       Date:  2013-12-17       Impact factor: 10.864

8.  In vitro study on the role of SOX9 in trastuzumab resistance of adenocarcinoma of the esophagogastric junction.

Authors:  Yingcai Hong; Huaisheng Chen; Zhanpeng Rao; Bin Peng; Hong Hu; Shaolin Lin; Zhenglei Xu
Journal:  Exp Ther Med       Date:  2018-01-12       Impact factor: 2.447

Review 9.  Hereditary Factors in Esophageal Adenocarcinoma.

Authors:  Anna M J van Nistelrooij; Winand N M Dinjens; Anja Wagner; Manon C W Spaander; J Jan B van Lanschot; Bas P L Wijnhoven
Journal:  Gastrointest Tumors       Date:  2014-05-09

10.  Patients' Preferences for Surgical Management of Esophageal Cancer: A Discrete Choice Experiment.

Authors:  Esther W de Bekker-Grob; Eva J Niers; J Jan B van Lanschot; Ewout W Steyerberg; Bas P L Wijnhoven
Journal:  World J Surg       Date:  2015-10       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.